Alpha Tau treats first recurrent glioblastoma patient in Israel with Alpha DaRT under broad-access study

Alpha Tau Medical Ltd

Alpha Tau Medical Ltd

DRTS

0.00
  • Alpha Tau announced the first Alpha DaRT treatment of a recurrent glioblastoma patient in Israel, marking the first use outside the US.
  • The procedure was completed safely, with no unexpected complications, using a brain-specific delivery system to place sources into the tumor.
  • The patient tolerated the treatment well, supporting feasibility for use in a setting with no established standard of care at recurrence.
  • The case was performed under the ALL broad-access clinical protocol at Hadassah University Medical Center.
  • US clinical results were already presented via interim data from the REGAIN recurrent glioblastoma trial; enrollment is continuing following FDA clearance to proceed to full enrollment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230830PRIMZONEFULLFEED9750626) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.